This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.
* Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Exclusion Criteria:
* Known history of allergic reaction to Stapokibart Injection.
* Participants currently or plan participating in any interventional clinical trial.
* Participants with hematologic malignancies.
* Women with pregnant.
* Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
Primary outcome measure(s)
The incidence rate of adverse reactions (ADR). — From enrollment to the end of treatment at 10 weeks Number of of Adverse Reactions （ADRs） is calculated based on Adverse Events （AEs） and Serious Adverse Events （SAEs） that were assessed by the investigator as related to the study drug and categorized according to the Medical Dictionary for Regulatory Activities （MedDRA）.
Trial sites (1)
Facility
City
Region
Status
Beijing Tongren Hospital, CMU
Beijing
China
More Chengdu Kangnuoxing Biopharma,Inc. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.